OS Therapies’ (OSTX) Buy Rating Reaffirmed at D. Boral Capital

OS Therapies (NYSE:OSTX)‘s stock had its “buy” rating reiterated by equities research analysts at D. Boral Capital in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $20.00 price objective on the stock.

Several other research analysts have also issued reports on OSTX. Maxim Group increased their price target on shares of OS Therapies from $8.00 to $15.00 and gave the stock a “buy” rating in a research note on Thursday, January 16th. Lake Street Capital started coverage on shares of OS Therapies in a report on Wednesday, April 2nd. They set a “buy” rating and a $19.00 target price for the company. Three equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, OS Therapies presently has a consensus rating of “Buy” and a consensus target price of $18.00.

OS Therapies Stock Down 8.4 %

Shares of OSTX stock opened at $1.31 on Monday. The business’s fifty day moving average is $1.70 and its 200 day moving average is $2.63. OS Therapies has a twelve month low of $1.26 and a twelve month high of $7.00.

Insider Buying and Selling

In related news, major shareholder Shalom Auerbach sold 16,720 shares of the business’s stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $6.74, for a total value of $112,692.80. Following the completion of the transaction, the insider now directly owns 2,531,211 shares in the company, valued at $17,060,362.14. The trade was a 0.66 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 13.80% of the stock is currently owned by company insiders.

Institutional Trading of OS Therapies

An institutional investor recently raised its position in OS Therapies stock. CM Management LLC increased its holdings in OS Therapies Inc (NYSE:OSTX) by 120.1% in the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 110,044 shares of the company’s stock after buying an additional 60,044 shares during the quarter. CM Management LLC owned about 0.51% of OS Therapies worth $471,000 at the end of the most recent reporting period.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.